CY1120168T1 - Rna συνθεση για θεραπεια μη-μικροκυτταρικων καρκινων πνευμονα (nsclc) - Google Patents
Rna συνθεση για θεραπεια μη-μικροκυτταρικων καρκινων πνευμονα (nsclc)Info
- Publication number
- CY1120168T1 CY1120168T1 CY20181100467T CY181100467T CY1120168T1 CY 1120168 T1 CY1120168 T1 CY 1120168T1 CY 20181100467 T CY20181100467 T CY 20181100467T CY 181100467 T CY181100467 T CY 181100467T CY 1120168 T1 CY1120168 T1 CY 1120168T1
- Authority
- CY
- Cyprus
- Prior art keywords
- composition
- immunostimulatory
- vaccine
- active
- nsclc
- Prior art date
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 4
- 229960005486 vaccine Drugs 0.000 abstract 4
- 230000003044 adaptive effect Effects 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2007/008770 WO2009046738A1 (en) | 2007-10-09 | 2007-10-09 | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
EP08838033.2A EP2197481B1 (en) | 2007-10-09 | 2008-10-08 | Rna composition for treating non-small lung cancers (nsclc) |
PCT/EP2008/008503 WO2009046974A2 (en) | 2007-10-09 | 2008-10-08 | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120168T1 true CY1120168T1 (el) | 2018-12-12 |
Family
ID=39590300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100467T CY1120168T1 (el) | 2007-10-09 | 2018-05-03 | Rna συνθεση για θεραπεια μη-μικροκυτταρικων καρκινων πνευμονα (nsclc) |
Country Status (20)
Country | Link |
---|---|
US (6) | US20100291156A1 (pt) |
EP (2) | EP3375454B1 (pt) |
JP (3) | JP5139529B2 (pt) |
CN (1) | CN101820899B (pt) |
AU (1) | AU2008309930B2 (pt) |
BR (1) | BRPI0818318B8 (pt) |
CA (1) | CA2696768C (pt) |
CY (1) | CY1120168T1 (pt) |
DK (1) | DK2197481T3 (pt) |
ES (1) | ES2668926T3 (pt) |
HR (1) | HRP20180698T1 (pt) |
HU (1) | HUE037295T2 (pt) |
LT (1) | LT2197481T (pt) |
MX (1) | MX2010003766A (pt) |
NO (1) | NO2197481T3 (pt) |
PL (1) | PL2197481T3 (pt) |
PT (1) | PT2197481T (pt) |
RU (1) | RU2526510C2 (pt) |
SI (1) | SI2197481T1 (pt) |
WO (2) | WO2009046738A1 (pt) |
Families Citing this family (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US9724404B2 (en) | 2009-04-13 | 2017-08-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | HPV particles and uses thereof |
EP2281579A1 (en) * | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
CN101623503B (zh) * | 2009-08-06 | 2011-07-27 | 中国人民解放军第三军医大学 | 生存素与路易斯寡糖的复合物及其制备方法和应用 |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
EP2449113B8 (en) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
AU2012291101B2 (en) | 2011-07-29 | 2016-04-07 | Riken | Cell for use in immunotherapy which contains modified nucleic acid construct encoding Wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct |
US10316332B2 (en) | 2011-07-29 | 2019-06-11 | Riken | Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
SG10201607962RA (en) | 2012-03-27 | 2016-11-29 | Curevac Ag | Artificial nucleic acid molecules |
MX358706B (es) | 2012-03-27 | 2018-08-31 | Curevac Ag | Moleculas de acido nucleico artificiales que comprenden un top 5´utr. |
DK3578659T3 (da) | 2012-03-27 | 2024-02-05 | CureVac SE | Kunstige nukelinsyremolekyler til forbedret protein- eller peptidekspression |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
CA2841016A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Wt1 peptide cancer vaccine composition for transdermal administration |
RU2697443C2 (ru) * | 2013-02-05 | 2019-08-14 | Нитто Денко Корпорейшн | Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения |
CA2900975A1 (en) | 2013-02-12 | 2014-08-21 | Texas Tech University System | Composition and method for diagnosis and immunotherapy of lung cancer |
BR122021025267B1 (pt) | 2013-02-22 | 2023-12-05 | Curevac Ag | Partes de kit e composição farmacêutica compreendendo um inibidor da via de pd-1 |
BR112015018989B1 (pt) * | 2013-02-22 | 2023-11-14 | Curevac Ag | Combinação de vacina/inibidor da via de pd-1, inibidor da via de pd-1 e vacina de rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS |
MX369469B (es) | 2013-08-21 | 2019-11-08 | Curevac Ag | Vacuna contra el virus respiratorio sincitial. |
SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
SG11201510751YA (en) * | 2013-08-21 | 2016-03-30 | Curevac Ag | Composition and vaccine for treating prostate cancer |
EP3574916A1 (en) | 2013-08-21 | 2019-12-04 | CureVac AG | Composition and vaccine for treating lung cancer |
BR112016001192A2 (pt) | 2013-08-21 | 2017-08-29 | Curevac Ag | Vacina contra a raiva |
WO2015024666A1 (en) * | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Composition and vaccine for treating lung cancer |
CA2915730A1 (en) | 2013-08-21 | 2015-02-26 | Karl-Josef Kallen | A combination rsv/influenza a vaccine |
WO2015042325A1 (en) | 2013-09-18 | 2015-03-26 | Aura Biosciences, Inc. | Virus-like particle conjugates for diagnosis and treatment of tumors |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
KR102399799B1 (ko) | 2013-12-30 | 2022-05-18 | 큐어백 아게 | 인공 핵산 분자 |
US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
SG11201604198YA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Methods for rna analysis |
JP6584414B2 (ja) | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | 人工核酸分子 |
CA2935878C (en) | 2014-03-12 | 2023-05-02 | Curevac Ag | Combination of vaccination and ox40 agonists |
WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
PT3134131T (pt) | 2014-04-23 | 2022-03-24 | Modernatx Inc | Vacinas de ácidos nucleicos |
BR112016026980B1 (pt) | 2014-06-10 | 2022-05-03 | Curevac Real Estate Gmbh | Método para sintetizar uma molécula de rna de uma dada sequência |
WO2016077125A1 (en) | 2014-11-10 | 2016-05-19 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
EP3218508A4 (en) * | 2014-11-10 | 2018-04-18 | Modernatx, Inc. | Multiparametric nucleic acid optimization |
ES2791152T3 (es) | 2014-12-12 | 2020-11-03 | Curevac Ag | Moléculas de ácido nucleico artificiales para una expresión proteica mejorada |
EP4353257A2 (en) | 2015-04-13 | 2024-04-17 | CureVac Manufacturing GmbH | Method for producing rna compositions |
WO2016165831A1 (en) | 2015-04-17 | 2016-10-20 | Curevac Ag | Lyophilization of rna |
US10293058B2 (en) | 2015-04-22 | 2019-05-21 | Curevac Ag | RNA containing composition for treatment of tumor diseases |
WO2016172219A1 (en) * | 2015-04-24 | 2016-10-27 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation |
SG11201708867UA (en) | 2015-04-30 | 2017-11-29 | Curevac Ag | Immobilized poly(n)polymerase |
WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
DK3294326T3 (da) | 2015-05-15 | 2021-05-31 | Curevac Ag | Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion |
CN107530448A (zh) | 2015-05-20 | 2018-01-02 | 库瑞瓦格股份公司 | 包含长链rna的干粉组合物 |
EP3916091A3 (en) | 2015-05-20 | 2022-03-30 | CureVac AG | Dry powder composition comprising long-chain rna |
US11608513B2 (en) | 2015-05-29 | 2023-03-21 | CureVac SE | Method for adding cap structures to RNA using immobilized enzymes |
CN107873055B (zh) | 2015-05-29 | 2021-09-17 | 库瑞瓦格房地产有限公司 | 包括至少一个切向流过滤步骤的产生和纯化rna的方法 |
WO2017009376A1 (en) | 2015-07-13 | 2017-01-19 | Curevac Ag | Method of producing rna from circular dna and corresponding template dna |
TW201718638A (zh) | 2015-07-21 | 2017-06-01 | 現代治療公司 | 傳染病疫苗 |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
US20190218546A1 (en) | 2015-10-16 | 2019-07-18 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
US11413346B2 (en) | 2015-11-09 | 2022-08-16 | Curevac Ag | Rotavirus vaccines |
EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
EP3416683A1 (en) | 2016-02-17 | 2018-12-26 | CureVac AG | Zika virus vaccine |
US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
EP3448427A1 (en) | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
EP3452493A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Nucleic acid molecules and uses thereof |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
CA3024744A1 (en) * | 2016-05-17 | 2017-11-23 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung squamous cell carcinoma |
US20190194760A1 (en) | 2016-05-25 | 2019-06-27 | Curevac Ag | Novel biomarkers |
KR20190029576A (ko) | 2016-06-09 | 2019-03-20 | 큐어백 아게 | 핵산 카고용 하이브리드 담체 |
CA3029813A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
ES2928475T3 (es) | 2016-09-14 | 2022-11-18 | Modernatx Inc | Composiciones de ARN de alta pureza y métodos para su preparación |
MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
WO2018096179A1 (en) | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
EP3808380A1 (en) | 2016-12-08 | 2021-04-21 | CureVac AG | Rna for treatment or prophylaxis of a liver disease |
MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
US11141476B2 (en) | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
EP3558355A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Henipavirus vaccine |
EP3558354A1 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Lassa virus vaccine |
CA3051252A1 (en) | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
KR20190124750A (ko) | 2017-02-28 | 2019-11-05 | 사노피 | 치료적 rna |
WO2018167320A1 (en) | 2017-03-17 | 2018-09-20 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
BR112019015244A2 (pt) | 2017-03-24 | 2020-04-14 | Curevac Ag | ácidos nucleicos codificando proteínas associadas a crispr e usos dos mesmos |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
US11820728B2 (en) | 2017-04-28 | 2023-11-21 | Acuitas Therapeutics, Inc. | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US10034951B1 (en) | 2017-06-21 | 2018-07-31 | New England Biolabs, Inc. | Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity |
KR20200024905A (ko) | 2017-07-04 | 2020-03-09 | 큐어백 아게 | 신규 핵산 분자 |
US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
US11524033B2 (en) | 2017-09-05 | 2022-12-13 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
KR20200071081A (ko) | 2017-10-19 | 2020-06-18 | 큐어백 아게 | 신규 인공 핵산 분자 |
WO2019092153A1 (en) | 2017-11-08 | 2019-05-16 | Curevac Ag | Rna sequence adaptation |
EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
WO2019122371A1 (en) | 2017-12-21 | 2019-06-27 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
WO2020067453A1 (ja) * | 2018-09-28 | 2020-04-02 | 大日本住友製薬株式会社 | 注射用組成物 |
WO2020072914A1 (en) | 2018-10-04 | 2020-04-09 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed rna |
US11072808B2 (en) | 2018-10-04 | 2021-07-27 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed RNA |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
RU2696872C1 (ru) * | 2019-04-11 | 2019-08-07 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук" (Томский НИМЦ) | Способ прогнозирования неблагоприятного исхода при немелкоклеточном раке легкого |
CN112402596B (zh) * | 2019-08-22 | 2023-12-08 | 上海细胞治疗集团有限公司 | 多肽组合物及疫苗 |
CN110456079B (zh) * | 2019-09-20 | 2020-06-02 | 四川大学华西医院 | Tapbp自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
CN111471635B (zh) * | 2020-04-13 | 2022-02-15 | 江南大学 | 一种提高枯草芽孢杆菌核酸含量的方法 |
CN116096702A (zh) | 2020-07-16 | 2023-05-09 | 爱康泰生治疗公司 | 用于脂质纳米颗粒的阳离子脂质 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
KR20230053998A (ko) | 2021-10-15 | 2023-04-24 | (주)지노믹트리 | mRNA 발현을 위한 유전자 구조체 |
WO2024097894A1 (en) * | 2022-11-04 | 2024-05-10 | RNAimmune, Inc. | Compositions and methods of ribonucleic acid vaccines encoding nye-so-1 |
CN115998851A (zh) * | 2022-12-28 | 2023-04-25 | 四川康德赛医疗科技有限公司 | 一种个体化mRNA组合物、载体、mRNA疫苗及其应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US5804381A (en) * | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
DE69923840T2 (de) | 1999-09-09 | 2006-04-06 | Curevac Gmbh | Transfer von mRNAs unter Verwendung von polykationischen Verbindungen |
EP1330467B1 (en) | 2000-11-03 | 2007-05-02 | Washington University | Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
DE50214200D1 (de) * | 2001-06-05 | 2010-03-25 | Curevac Gmbh | Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt |
US7955845B2 (en) * | 2001-11-20 | 2011-06-07 | Dana Farber Cancer Institute, Inc. | Modified antigen-presenting cells |
DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
WO2005005615A2 (en) | 2003-07-08 | 2005-01-20 | Fox Chase Cancer Center | Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer |
US7842289B2 (en) * | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
DE102004035227A1 (de) * | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
EP1906997A2 (en) * | 2005-07-11 | 2008-04-09 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
RU2345788C2 (ru) * | 2005-09-02 | 2009-02-10 | ООО "Научно-практический центр медико-биологических проблем "ГОРМЕЗИС" | Способ лазерной вакцинации больных с метастатическими формами рака |
JP2010507361A (ja) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | 具体的には免疫刺激剤/アジュバントとしての、一般式(I):GlXmGn、または一般式(II):ClXmCnで表される核酸 |
DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
-
2007
- 2007-10-09 WO PCT/EP2007/008770 patent/WO2009046738A1/en active Application Filing
-
2008
- 2008-10-08 MX MX2010003766A patent/MX2010003766A/es active IP Right Grant
- 2008-10-08 EP EP18155886.7A patent/EP3375454B1/en active Active
- 2008-10-08 CN CN200880110920.1A patent/CN101820899B/zh not_active Expired - Fee Related
- 2008-10-08 CA CA2696768A patent/CA2696768C/en not_active Expired - Fee Related
- 2008-10-08 JP JP2010528312A patent/JP5139529B2/ja not_active Expired - Fee Related
- 2008-10-08 EP EP08838033.2A patent/EP2197481B1/en active Active
- 2008-10-08 LT LTEP08838033.2T patent/LT2197481T/lt unknown
- 2008-10-08 PT PT88380332T patent/PT2197481T/pt unknown
- 2008-10-08 SI SI200831951T patent/SI2197481T1/en unknown
- 2008-10-08 WO PCT/EP2008/008503 patent/WO2009046974A2/en active Application Filing
- 2008-10-08 NO NO08838033A patent/NO2197481T3/no unknown
- 2008-10-08 HU HUE08838033A patent/HUE037295T2/hu unknown
- 2008-10-08 BR BRPI0818318A patent/BRPI0818318B8/pt not_active IP Right Cessation
- 2008-10-08 DK DK08838033.2T patent/DK2197481T3/en active
- 2008-10-08 US US12/682,213 patent/US20100291156A1/en not_active Abandoned
- 2008-10-08 ES ES08838033T patent/ES2668926T3/es active Active
- 2008-10-08 RU RU2010118024/10A patent/RU2526510C2/ru active
- 2008-10-08 AU AU2008309930A patent/AU2008309930B2/en not_active Ceased
- 2008-10-08 PL PL08838033T patent/PL2197481T3/pl unknown
-
2012
- 2012-11-15 JP JP2012251602A patent/JP6012423B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-25 US US13/750,664 patent/US9352028B2/en not_active Expired - Fee Related
-
2015
- 2015-01-16 JP JP2015007164A patent/JP6031131B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-03 US US15/145,746 patent/US20160346370A1/en not_active Abandoned
- 2016-05-03 US US15/145,540 patent/US20160317636A1/en not_active Abandoned
-
2018
- 2018-05-03 CY CY20181100467T patent/CY1120168T1/el unknown
- 2018-05-04 HR HRP20180698TT patent/HRP20180698T1/hr unknown
- 2018-05-21 US US15/985,443 patent/US20180256694A1/en not_active Abandoned
-
2021
- 2021-07-19 US US17/378,954 patent/US20220096616A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120168T1 (el) | Rna συνθεση για θεραπεια μη-μικροκυτταρικων καρκινων πνευμονα (nsclc) | |
CY1123258T1 (el) | Μεθοδος θεραπειας για τον καρκινο | |
CY1125260T1 (el) | Παραγοντες δεσμευσης tigit και χρησεις τους | |
CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
CY1125144T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης | |
MX2023002251A (es) | Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer. | |
CY1119960T1 (el) | Μεθοδοι για την αυξηση της αποτελεσματικοτητας της folr1 θεραπειας του καρκινου | |
CY1122247T1 (el) | Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3 | |
MX2019010972A (es) | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. | |
CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
NZ737471A (en) | Hydrophilic linkers for conjugation | |
WO2015105995A3 (en) | Targeted therapy for small cell lung cancer | |
WO2016196298A8 (en) | Therapeutic and diagnostic methods for cancer | |
EP3964527A3 (en) | Combination therapy for cancer | |
WO2015112805A8 (en) | Human antibodies to pd-l1 | |
WO2018104909A3 (en) | Dna methylation profiling for t-cell immunotherapy | |
MX2010003768A (es) | Composicion para tratamiento de cancer de prostata (pca). | |
BR112015007184A2 (pt) | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer | |
CR10530A (es) | Anticuerpos anti-dlla4 y metodos que los usan | |
MX351889B (es) | Composiciones y métodos anti-cxcr1. | |
NO20072179L (no) | Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer | |
DK1904102T3 (da) | ANTI-CCR7-receptorantistoffer til behandling af cancer | |
EP3895725A3 (en) | A method for treating tumor by using recombinant interferon with changed spatial configuration | |
TR201901422T4 (tr) | Tümörlerin tedavisinde kullanım için korteksolon 17A,21-diesterleri. | |
MX2023011105A (es) | Virus oncoliticos optimizados y usos de los mismos. |